Microbiome Focused Product
Our single strain Live Biotherapeutics are dedicated to unlocking the therapeutic value of Christensenella, as well as other keystone microbiome bacteria.
This program is built on first-in-class scientific publications that have identified christensenella as a cornerstone of healthy human intestinal microbiota. The bacterial strain specifically selected for this program comes from LNC Therapeutics’ proprietary library.
LNC01 showed strong preclinical efficacy results in preclinical animal models.
By finalizing the industrialization process for the manufacture of clinical batch of its Xla1 product candidate, LNC Therapeutics accomplished a key challenge in the production of anaerobic gut bacteria.
Read cGMP manufacturing press release
LNC Therapeutics received FDA Investigational New Drug Approval to assess the safety and tolerability of Xla1 in adults with obesity and metabolic abnormalities in a Phase 1 clinical trial.Read IND approval press release
LNC02 & LNC03
Many inflammatory disorders have been associated with alterations of the gut microbiome. LNC Therapeutics therefore focusses on restoring the gut microbial symbiosis specifically altered in some inflammatory pathologies using carefully selected single strain bacteria.
Our approach is supported by compelling epidemiological and clinical data that have demonstrated a strong link between the presence of keystone bacteria and reduced risks of developing inflammatory bowel disorders.
Our programs aim at selecting single strain bacteria with a significant anti-inflammatory activity for multiple indications. We expect that at least one clinical candidate will complete IND filing by end of 2021.
We are closely collaborating with Pr. Philippe Langella and his team, from the Micalis Institute (joint research unit between INRA, AgroParisTech and Paris-Saclay University), a cutting-edge European microbiology research organization.
Read our press release
General review of gut microbiome changes in IBD showing consistant association between CD and a loss of Christensenellacea
Pittayanon, R., Lau, J.T., Leontiadis, G.I., Tse, F., Yuan, Y., Surette, M., and Moayyedi, P. (2019). Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: a Systematic Review. Gastroenterology 1–52.
Important paper showing that loss of Christensenella is predictive of CD flare.
Braun, T., Di Segni, A., BenShoshan, M., Neuman, S., Levhar, N., Bubis, M., Picard, O., Sosnovski, K., Efroni, G., Farage Barhom, S., et al. (2019). Individualized Dynamics in the Gut Microbiota Precede Crohnʼs Disease Flares. Am. J. Gastroenterol. 1–10.
Over the last 5 years, there has been increasing evidence that the gut microbiome was associated with neurological and behavioral disorders, which led to the so called “gut-brain axis” concept.
Multiple complex mechanisms of action are at play in this relationship, and although a lot still to discover, there is strong support for an action of the gut microbiome on neurotransmitter and neuroinflammation.
LNC Therapeutics is therefore initiating research in this exciting area to harness the potential of carefully selected bacteria strains of Christensenellaceae to treat mood disorders, such as depression or anxiety.
In April 2020, LNC Therapeutics entered into an exclusive license agreement with Spanish National Research Council (CSIC), for its patent application dedicated to the therapeutic use of Christensenella gut bacteria in mood disorders
Read our press release
Pr. John Cryan, a neuropharmacologist and microbiome expert from the University College Cork, shares surprising facts and insights about how our thoughts and emotions are connected to our gut.
Discover John Cryan on TEDMED